secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001193125-25-003547
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

NeuroPace Reports Preliminary 2024 Revenue Above Guidance and Appoints Scott Huennekens to Board
--------------------------------------------------------------------------------

- Preliminary unaudited Q4 2024 revenue expected $21.0M-$21.5M (17-19% growth vs Q4 2023), full year $79.4M-$79.9M (21-22% growth), above initial guidance of $73M-$77M.
- Cash and short-term investments as of Dec 31, 2024 expected $52.8M; shares outstanding 30,145,039.
- Scott Huennekens appointed to Board of Directors effective Jan 6, 2025; granted options for 15,507 shares at $11.93.
- NAUTILUS trial one-year follow-up on track for March 2025; data lock and analysis in Q2 2025.
- Management to present at J.P. Morgan Healthcare Conference Jan 15 and host Investor Day Jan 28 in NYC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000119312525003547/0001193125-25-003547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000119312525003547/d889166d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-003547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer